* Please be kindly noted that our services and products can only be used for research by organizations or companies and are not intended for individual use.
Inhibitor of apoptosis proteins (IAPs), including cIAP1, cIAP2, and XIAP, are important E3 ligase systems for targeted protein degradation strategies such as SNIPERs and IAP-recruiting PROTACs. For drug discovery teams, the quality of the IAP ligand determines not only binary binding to the E3 ligase, but also linker exit-vector compatibility, ternary complex formation, cellular degradation potency, and the balance between target protein degradation and IAP autodegradation. However, designing practical IAP ligands is challenging because small structural changes around the Smac-mimetic core, stereocenter configuration, BIR-domain interaction pattern, solubility profile, and conjugation handle can strongly affect degrader performance.
BOC Sciences provides specialized IAP ligand design services for pharmaceutical, biotechnology, and academic research teams developing IAP-based degraders, SNIPER molecules, IAP ligand-linker intermediates, and E3 ligase recruitment probes. Our service integrates structure-guided ligand design, medicinal chemistry optimization, synthetic feasibility assessment, linker attachment planning, binding evaluation, and degrader-oriented functional validation. Whether clients need a new cIAP1-preferred ligand, an XIAP-biased scaffold, a functionalized IAP ligand-linker building block, or a ligand optimized for incorporation into a heterobifunctional degrader, our team supports each stage with a practical, data-driven design strategy.
We design IAP ligands by analyzing BIR-domain binding pockets, Smac-mimetic interaction motifs, hydrogen-bonding networks, hydrophobic subpockets, and stereochemical requirements. Through molecular docking for protein-ligand studies and medicinal chemistry evaluation, we help clients identify ligand scaffolds with improved binding orientation, accessible exit vectors, and degrader-compatible physicochemical properties.
cIAP1, cIAP2, and XIAP Ligand Optimization
Different IAP family members may require distinct ligand design strategies. BOC Sciences supports scaffold modification for cIAP1/cIAP2 recruitment, XIAP BIR-domain engagement, or balanced pan-IAP binding, depending on the degradation mechanism required by the project. Our ligand design for E3 ligase platform enables rational optimization of affinity, selectivity tendency, functional group tolerance, and synthetic accessibility.
Smac-Mimetic Scaffold Engineering
Many IAP ligands are inspired by the N-terminal AVPI motif of Smac/DIABLO. We engineer monovalent and bivalent Smac-mimetic scaffolds by modifying amino acid mimics, constrained rings, hydrophobic substituents, polar groups, and stereochemical elements. This service is particularly valuable when clients need to convert a known IAP antagonist into a functional E3 ligase ligand for degrader construction.
Functional Handle and Exit-Vector Design
A high-affinity IAP ligand may fail in a degrader if the linker attachment site disrupts IAP binding or creates an unfavorable ternary complex geometry. We identify suitable exit vectors, introduce functional handles, and evaluate linker attachment positions to support downstream linker design and optimization. Common handle strategies include amine, acid, alkyne, azide, and other conjugation-ready groups selected according to project chemistry.
IAP Ligand-Linker Intermediate Development
We design and synthesize IAP ligand-linker intermediates for rapid assembly of SNIPERs and IAP-based PROTAC candidates. The service covers ligand-linker junction selection, PEG/alkyl/hybrid linker compatibility, terminal functional group planning, route scouting, purification, and analytical confirmation. Clients can also access related E3 ligase ligand-linker conjugate products to accelerate early degrader exploration.
Binding and Functional Characterization
Designed IAP ligands can be evaluated through biochemical, biophysical, and cell-based assays. We support binding affinity measurement, IAP engagement analysis, cIAP1 degradation monitoring, target protein degradation readouts, and structure-activity relationship interpretation to guide the next design cycle.
Need a More Effective IAP Recruitment Strategy?
From Smac-mimetic scaffold design to ligand-linker optimization, we help you build IAP ligands tailored for degrader discovery.
cIAP1 autodegradation and target degradation readouts
Analytical and Data Interpretation Platform
Our integrated analytical system helps clients understand why one IAP ligand design succeeds while another fails.
Structure confirmation by NMR and HRMS
HPLC / LC-MS purity and stability profiling
SAR mapping across ligand, linker, and target warhead variables
Advantages
Key Advantages of Custom IAP Ligand Design
Expanded E3 Ligase Options
IAP ligands provide an alternative recruitment strategy when CRBN- or VHL-based degraders do not deliver the desired degradation profile. This enables teams to explore new E3 ligase biology and identify degrader designs better matched to the target protein and cellular context.
Degrader-Oriented Ligand Engineering
Our design strategy focuses on how the ligand performs inside a complete degrader, not only how tightly it binds IAP alone. Exit vector, linker tolerance, ternary complex geometry, and cellular activity are considered from the beginning.
Improved SAR Decision-Making
By combining scaffold design, synthesis, binding data, and degradation readouts, BOC Sciences helps clients distinguish ligand-driven limitations from linker, target warhead, or cellular permeability issues.
Flexible Project Entry Points
Clients may start with a published IAP ligand, an internal scaffold, a virtual hit, a ligand-linker concept, or a failed degrader requiring redesign. We adapt the workflow to the available data and project objective.
Workflow
Our IAP Ligand Design Service Workflow
01
Project Consultation and Design Goal Definition
We clarify the intended IAP family member, target protein, degrader format, linker preference, available warhead, assay system, and key project challenges to define a practical ligand design plan.
02
IAP Binding Site and Scaffold Analysis
Our scientists analyze BIR-domain structures, known Smac-mimetic binding modes, potential ligand hot spots, and scaffold liabilities to select suitable starting points.
03
Virtual Design and Candidate Prioritization
Multiple analog concepts are generated and prioritized according to predicted binding pose, exit-vector accessibility, synthetic feasibility, physicochemical profile, and degrader assembly compatibility.
04
Custom Synthesis and Functionalization
Selected IAP ligands are synthesized with appropriate functional handles or linker-ready groups, followed by analytical confirmation using suitable chemical characterization methods.
05
Ligand-Linker Assembly Evaluation
We assess how the designed ligand behaves after linker attachment, including steric impact, solubility change, synthetic stability, and compatibility with target ligand conjugation.
06
Binding and IAP Engagement Testing
Candidate ligands can be evaluated for IAP binding and cellular engagement to confirm that chemical modifications preserve productive E3 ligase recognition.
07
Degrader-Oriented Functional Assessment
When incorporated into degrader candidates, IAP ligands are assessed through target protein degradation, cIAP1 modulation, concentration-response behavior, and comparative SAR analysis.
08
Optimization Report and Next-Round Design
BOC Sciences delivers a data-supported summary covering chemical structures, synthesis results, analytical data, assay interpretation, and recommended next design directions.
Start Your IAP Ligand Design Project Today
Partner with BOC Sciences to develop customized IAP ligands for SNIPERs, IAP-based PROTACs, and E3 ligase recruitment studies.
Our team understands how E3 ligase ligand design influences target degradation, ternary complex formation, linker selection, and cellular activity in targeted protein degradation programs.
Integrated Design-to-Validation Support
We connect computational design, medicinal chemistry, custom synthesis, analytical characterization, binding assays, and degradation evaluation into a coherent project workflow.
Customized IAP Family Strategy
Depending on the project objective, we can explore cIAP1-focused, XIAP-oriented, or broader IAP-recruiting ligand designs and adjust the scaffold strategy accordingly.
Practical Synthetic Feasibility
Each proposed ligand is reviewed for route feasibility, functional group compatibility, purification practicality, and downstream degrader assembly potential.
Flexible Service Models
BOC Sciences supports single-step ligand design, ligand-linker synthesis, assay validation, SAR rescue projects, and complete IAP-based PROTAC development workflows.
Clear Technical Communication
Clients receive structured reports, interpretable SAR rationale, and practical recommendations that support rapid internal decision-making across medicinal chemistry and biology teams.
Applications
Applications of IAP Ligand Design Services
SNIPER Molecule Development
Custom IAP ligands can be incorporated into SNIPER molecules to recruit IAP E3 ligases for target protein ubiquitination and proteasomal degradation studies.
IAP-Based PROTAC Construction
IAP ligands provide alternative E3 ligase recruitment modules for PROTAC programs, especially when clients need to compare multiple E3 systems for the same target protein.
E3 Ligase Recruitment Probe Design
Functionalized IAP ligands can be used to build chemical probes for studying IAP engagement, E3 ligase recruitment, and ubiquitination-related mechanisms in cellular systems.
Ligand-Linker Building Block Preparation
Designed IAP ligand-linker intermediates allow medicinal chemistry teams to rapidly assemble degrader libraries by coupling to different target protein ligands.
Target Degradation SAR Exploration
By varying IAP ligand scaffold, linker exit vector, and linker length, researchers can identify which structural features drive the most productive degradation profile.
Rescue of Low-Activity Degrader Programs
When a degrader shows weak degradation despite acceptable target warhead binding, redesigning the IAP ligand or ligand-linker junction can reveal new optimization directions.
Case Study
Client Success Stories: IAP Ligand Design
Project Background
A US biotechnology company was developing an IAP-recruiting degrader against a disease-relevant kinase. The initial molecule used a published Smac-mimetic ligand and a flexible PEG linker, but cellular degradation was inconsistent across cell models. The client suspected that the IAP ligand exit vector and linker attachment position were limiting productive ternary complex formation.
Technical Challenges
The original ligand retained measurable IAP binding but showed poor tolerance to linker extension at the selected attachment site. In addition, the full degrader had high lipophilicity, low aqueous handling performance, and strong cIAP1 autodegradation at concentrations where target degradation was still modest.
BOC Sciences Solutions
Binding Mode Reassessment: We modeled the ligand within the cIAP1 BIR3 binding pocket and identified two alternative solvent-exposed exit vectors that were less likely to disrupt key Smac-mimetic interactions.
Ligand Analog Design: Twelve IAP ligand analogs were proposed with modified hydrophobic caps, constrained ring substitutions, and polar side-chain replacements to balance cIAP1 engagement and degrader-like physicochemical properties.
Ligand-Linker Screening: Six ligand-linker intermediates were synthesized using PEG, alkyl, and hybrid linkers, then coupled to the client's kinase ligand for comparative degradation evaluation.
Project Outcomes
BOC Sciences identified a redesigned cIAP1 ligand-linker module that produced stronger and more reproducible kinase degradation than the original design. Among the six degrader variants, one hybrid-linker candidate achieved the best balance between target degradation and manageable cIAP1 modulation, while two additional analogs provided useful SAR backup options for the client's next optimization round.
Project Background
A European pharmaceutical research team requested support for an XIAP-biased IAP ligand to build degraders targeting BET family proteins. Their internal design showed promising BRD4 binding but weak degradation activity, suggesting that E3 ligase recruitment and ternary complex geometry required further optimization.
Technical Challenges
The available IAP ligand had a bulky substituent near the proposed linker attachment site, creating steric pressure after coupling to the BET ligand. The team also needed a ligand design that preserved XIAP binding while improving solubility and synthetic flexibility.
BOC Sciences Solutions
XIAP Pocket Mapping: We analyzed the BIR3 domain interaction pattern and prioritized modifications that retained the AVPI-mimetic recognition elements while reducing steric congestion near the linker exit vector.
Scaffold Refinement: Fifteen XIAP-oriented ligand analogs were designed, including ring-constrained, polar-substituted, and amide-replaced variants to explore binding, solubility, and linker tolerance.
Functionalized Ligand Preparation: Four top-ranked analogs were synthesized with amine- and acid-functional handles, enabling rapid coupling to multiple BET ligand-linker formats.
Project Outcomes
The optimized XIAP-biased ligand series provided clear SAR direction for the client's BET degrader program. One ligand-linker configuration showed improved BRD4 degradation at lower test concentrations than the starting molecule, while maintaining acceptable chemical stability during assembly. The client selected this design as the preferred IAP recruitment module for expanded cellular profiling.
IAP ligands are used to recruit inhibitor of apoptosis protein family E3 ligases to a target protein through a PROTAC or SNIPER molecule. By bringing the target protein into proximity with the ubiquitin-proteasome system, IAP ligands help promote target ubiquitination and subsequent degradation. In targeted protein degradation research, IAP ligands provide an alternative E3 recruitment strategy beyond commonly used CRBN or VHL ligands, expanding the design space for degraders and enabling researchers to evaluate different degradation mechanisms, cellular contexts, and target-specific responses.
How is a suitable IAP ligand selected?
Selecting a suitable IAP ligand requires consideration of the project goal, target protein biology, cellular model, intended degradation mechanism, and overall molecular properties. Key factors include IAP subtype preference, binding affinity, available modification sites, linker attachment direction, molecular weight, polarity, solubility, and potential influence on ternary complex formation. BOC Sciences can support IAP ligand selection through scaffold evaluation, structural analysis, synthetic feasibility assessment, and linker-compatible design, helping clients identify ligand candidates suitable for IAP-recruiting PROTAC or SNIPER development.
What are the main challenges in IAP ligand design?
The main challenge in IAP ligand design is not only achieving strong IAP binding, but also maintaining productive geometry within the complete degrader molecule. Some IAP ligand scaffolds may be structurally complex or relatively hydrophobic, and linker introduction can affect IAP engagement, target recruitment, cellular activity, or overall physicochemical behavior. In addition, IAP family members such as cIAP1 and XIAP may differ in expression pattern, domain architecture, and functional context. Therefore, BOC Sciences applies linker-position scanning, linker length optimization, polarity adjustment, and conformational refinement to reduce design risk and improve the suitability of IAP ligands for targeted protein degradation projects.
Which PROTAC projects are suitable for IAP ligands?
IAP ligands are especially useful for projects that aim to explore non-CRBN and non-VHL E3 ligase recruitment strategies, develop SNIPER-like degraders, improve degradation in specific cellular backgrounds, or study IAP-mediated ubiquitination mechanisms. They can also be considered when CRBN- or VHL-based PROTACs show limited degradation efficiency, insufficient selectivity, or structural optimization bottlenecks. For target proteins that require alternative E3 ligase engagement, IAP ligands may provide a valuable route to expand degrader diversity and generate comparative structure-degradation relationship data.
What support can BOC Sciences provide for IAP ligand design?
BOC Sciences provides integrated support for IAP Ligand Design Services, covering ligand scaffold selection, structural modification, attachment site design, linker compatibility evaluation, and IAP-recruiting PROTAC design strategy. Based on the client’s target protein ligand, degradation objective, and cellular model requirements, we can design candidate ligands for recruiting cIAP1, XIAP, or related IAP family members. For early-stage projects, we help compare multiple IAP ligand scaffolds and linker strategies; for lead optimization projects, we support refinement of activity retention, solubility, cell permeability, and degradation window to better align IAP ligand design with targeted protein degradation research needs.
Testimonials
Client Testimonials on IAP Ligand Design Services
Clear SAR Guidance
"BOC Sciences helped us understand why our original IAP ligand was not translating into efficient degradation. Their exit-vector analysis and analog design gave our chemistry team a much clearer optimization path."
— Dr. Reynolds, Medicinal Chemistry Director
Practical Ligand-Linker Design
"The team did not simply provide ligand structures; they considered synthesis, linker coupling, and cellular degrader performance together. That integrated perspective was highly valuable for our SNIPER program."
— Ms. Hartmann, Project Manager
Reliable Technical Communication
"We appreciated the detailed design rationale behind each IAP ligand analog. The reports connected structural hypotheses with assay data, which made internal decision-making much more efficient."
— Dr. Patel, Principal Scientist
Strong Degrader Design Expertise
"BOC Sciences quickly identified that our limitation was not the target warhead, but the IAP ligand-linker junction. Their redesign produced a more useful degrader series for our follow-up studies."
— Senior Scientist, Oncology Discovery Team
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Quick Inquiry
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
We invite you to contact us at or through our contact form above for more information about our services and products.
Expanded E3 Ligase Options
